asembix 5 mg/5 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 5 mg/5 mg
prestilol 10 mg/10 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 10 mg/10 mg
prestilol 10 mg/5 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 10 mg/5 mg
prestilol 5 mg/10 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 5 mg/10 mg
asembix 10 mg/10 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 10 mg/10 mg
prestilol 5 mg/5 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 5 mg/5 mg
prestilol 5 mg/10 mg apvalkotās tabletes
les laboratoires servier, france - bisoprololi fumaras, perindoprili argininum - apvalkotā tablete - 5 mg/10 mg
lodoz 5 mg/6,25 mg apvalkotās tabletes
merck romania srl, romania - bisoprololi fumaras, hydrochlorothiazidum - apvalkotā tablete - 5 mg/6,25 mg
lodoz 5 mg/6,25 mg apvalkotās tabletes
merck romania srl, romania - bisoprololi fumaras, hydrochlorothiazidum - apvalkotā tablete - 5 mg/6,25 mg
xtandi
astellas pharma europe b.v. - enzalutamide - prostatas audzēji - endokrīnā terapija - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.